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1. Introduction
Tissue repair is a natural process occurring any time the skin is injured. Repair is achieved
through different successive phases: inflammation, formation of granulation tissue, forma‐
tion of the extracellular matrix (ECM), and remodeling. ECM plays an important role in tis‐
sue regeneration representing the principal component of the dermal skin layer. The
composition of ECM includes proteoglycans, hyaluronic acid, collagen, fibronectin and elas‐
tin. As well as providing a structural support for cells, some components of the ECM bind to
growth factors, creating a reservoir of active molecules that can be rapidly mobilized follow‐
ing injury to stimulate cell proliferation and migration [1].
Acute wounds, such as traumatic or surgical wounds, generally require topical treatments
leading to complete scar formation within 14 days. Treatment modalities, from topical treat‐
ments administered as a support for the physiological mechanisms of scarring to surgical re‐
pair with skin grafts, are usually chosen according to: dimension, location, and severity of
the lesion; exposition of visceral or skeletal structures; age of the patient; risks related to oth‐
er illnesses.
Some lesions, despite careful clinical examination, good physiopathologic classification, and
adequate treatment (e.g. etiologic therapy, debridement and disinfection of the lesion, ‘‘hu‐
midification’’ of the surface) do not heal but achieve only temporary clinical improvement.
Chronic wounds represent a state in which healing has stagnated.
Some studies showed that in chronic wounds the hyperproliferation of the edges inhibits the
apoptosis of fibroblasts and keratinocytes [2]. Anomalies of the phenotype have also been
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associated with fibroblasts, such as altered morphology and a slower rate of proliferation
[3,4]. Moreover, the fibroblasts obtained from chronic ulcers and cultivated in vitro have
shown lesser response to exogenous application of growth factors such as platelet-derived
growth factor [5,6]. This is because of fibroblasts being senescent and not truly responsive to
stimuli, which would explain why the local application of growth factors to a chronic
wound will not heal it [7,8]. In many chronic wounds, increased levels of inflammatory cells
lead to elevated levels of proteases that seem to degrade the ECM components, growth fac‐
tors, protein and receptors that are essential for healing [9].
Many surgical techniques and various types of advanced dressings are used for the treat‐
ment of these ulcers, assuming that the physiologic processes of tissue repair are competent
and that the lesion can heal ‘‘spontaneously’’; this occurs quite frequently, but there are ul‐
cers, usually defined as “complex”, which do not heal within an acceptable timeframe, de‐
spite a correct diagnostic and therapeutic procedure, or relapse rapidly. This may be due to
concomitant systemic pathologies (e.g. diabetes, immunodeficiency, cardiac failure) and/or
to the presence of local factors (e.g. oedema, arterial or venous failure, infections) that inhibit
the healing process. The lack of healing of the ulcer, even for years, affects the whole circum‐
ference of the leg, often involving deep structures such as aponeuroses and tendons. In such
cases, a reconstructive surgical operation using skin grafts must always be considered,
though it may also be difficult or likely to fail because of the position, width, and depth of
the lesion(s).
When dealing with large full-thickness wounds of the lower limbs, the use of reconstructive
operations with autologous skin grafting is widespread. Epidermis with a superficial part of
the dermis is harvested with a dermatome from an undamaged skin donor site and applied
to the full-thickness wound. Being applied to the wound, capillaries of the split skin graft
(SSG) form anastomoses or “plug in” into the existing capillary network to provide nutrients
for graft survival; this is referred to as graft “take”. In the case of an extensive wound, donor
sites are limited and in such cases, meshing techniques can be used meaning grafted skin is
uniformly perforated and stretched to cover greater areas of the wound.
Nevertheless, full-thickness skin grafts require the taking of a sample, determining the crea‐
tion of a wound that is itself deep and susceptible to complications such as infections and
retractions of the scar, and precludes the use of the same site for the taking of further sam‐
ples [10]. For this reason, one tends to prefer partial-thickness skin grafts, which in some
cases may fail to attach and tend to retract, leading to unsatisfying results. That is for the
most part due to the paucity or absence of derma in the partial-thickness skin grafts, as the
dermal matrix plays a fundamental role in determining the success of a skin graft [11,12].
In these patients a new therapeutic perspective is “regenerative surgery” with the use of tis‐
sue-engineered products. In fact recognition of the importance of the ECM in wound heal‐
ing has led to the development of wound products that aim to stimulate or replace the ECM.
These tissue-engineered products comprise a reconstituted or natural collagen matrix that
mimics the structural and functional characteristics of native ECM [13]. When placed into
the wound bed, the three-dimensional matrix provides a temporary scaffold or support into
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which cells can migrate and proliferate in an organized manner, leading to tissue regenera‐
tion and ultimately wound closure.
An ideal replacing skin product should principally contain these factors:
• the ECM;
• dermal fibroblasts;
• a semipermeable membrane between dermis and epidermis.
These components may act synergistically as part of a fully integrated tissue to protect the
underlying tissues of a wound bed and to direct healing of the wound. Dermis containing
fibroblasts could be necessary for the maintenance of the epidermal cell population.
All tissue-engineered skin substitute bioconstructs need to comply with three major require‐
ments. They must be: safe for the patient, clinically effective, and convenient in handling
and application. In general, such biomaterials must not be toxic, immunogenic or cause ex‐
cessive inflammation, and should also have no or low level of transmissible disease risk. The
biomaterial for skin reconstruction should be biodegradable, repairable and able to support
the reconstruction of normal tissue, with physical and mechanical properties similar to those
of the skin it replaces. It should provide pain relief, prevent fluid and heat loss from the
wound surface and protect the wound from infection. It is also of great advantage if the skin
substitute bioconstruct is cost-effective, readily available, user-friendly and with a long shelf
life. No tissue-engineered skin replacement biomaterials currently available in commerce
possess all the above-mentioned properties nor can any fully replace the functional and ana‐
tomical properties of the native skin. There are, however, a number of bioengineered skin-
replacement products suitable for wound-healing purposes which are currently available to
clinicians. In general, these tissue replacements only partially address skin functional re‐
quirements and surgeons tend to use different products to achieve specific purposes.
Tissue-engineered skin products may be either cellular, containing living cells (Table 1), or
acellular, biologically inert (Table 2), and sourced from:
• Biological tissue: animal (e.g. equine/bovine/porcine); human (e.g. cadaveric skin); plant
(e.g. containing oxidized regenerated cellulose/collagen)
• Synthetic materials
• Composite materials (containing two or more components, which may be biological or
synthetic).
Different types of tissue-engineered products are available and confusion exists concerning
the used terminology. Products may be classified as skin substitutes, xenografts, allografts
or collagen dressings. “Skin substitutes” is an umbrella term for a group of products. De‐
pending on individual characteristics, they may substitute or replace all or some compo‐
nents that compose normal skin (e.g. epidermis and/or dermis, cells and matrix). They can
be bilayered, acellular or cellular, synthetic or biological and may consist of a synthetic epi‐
dermis and a collagen-based dermis to encourage formation of new tissue. In products with
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a synthetic epidermis, this may act as a temporary wound covering. Alternatively, these
products may be described as biological dressings in that they serve as a protective wound
cover. However, while most wound dressings need to be changed frequently, matrices pro‐
vide a scaffold for tissue repair and therefore must remain in the wound for a sufficient
length of time [23].
Product Industry Scaffold Type Cell Source Indicated forAcute Wounds
Indicated for
Chronic
Wounds
Epicel® Genzyme
Autologous
keratinocytes, murine
fibroblasts
Dermal
+Epidermic Autograft + +
Epidex® Modex Nitrocellulose Epidermic Autograft + +
MySkin CellTRan Ltd.
Cultured
Keratinocytes
(subconfluent cell
sheet)+silicon support
layer with a specially
formulated surface
coating
Epidermic Autograft + +
Cell Spray Clinical CellCulture
Non-/cultured
Keratinocytes Epidermic Autograft + +
Bioseed-S BioTissueTechnologies
Cultured
Keratinocytes
(subconfluent cell
sheet)+fibrin sealant
Epidermic Autograft + +
Epibase LaboratoiresGenevirier
Cultured
Keratinocytes
(subconfluent cell
sheet)
Epidermic Autograft + +
Apligraf OrganogenesisInc.
Cultured keratinocytes
and fibroblast and
bovine collagen
Dermal +
Epidermic Allograft + +
Orcel
Ortec
International,
Inc. NY
Cultured keratinocytes
and fibroblast and
bovine collagen
sponge
Dermal +
Epidermic Allograft + +
PolyActive HC Implants Bv,Leiden
Cultured keratinocytes
and fibroblast in
PEO/PBT
Dermal +
Epidermic Allograft + +
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Product Industry Scaffold Type Cell Source Indicated forAcute Wounds
Indicated for
Chronic
Wounds
Trancyte® ATS
Silicon film, Nylon
mesh, Porcine
collagen+cultured
neonatal fibroblast
Dermal
Allo- and
synthetic
graft
+ -
Dermagraft® ATS
PLA/PGA+ ECM
derived from
fibroblast
Dermal
Allo - and
synthetic
graft
+ +
Graftskin Organogenesis
Bovine collagen+
human keratinocytes
and fibroblast
Dermal +
Epidermic Allograft + +
CSS® OrtecInternational
Cross-linked bovine
collagen and human
cells
Dermal +
Epidermic Allograft + +
Keratinocytes crops
Lab. Ingegneria
tessutale
Università
Milano
HYAFF® Epidermic Autograft + +
Laserskin®Autograft
HyalograftTM 3D FAB
Cultured keratinocytes
and fibroblast
+HYAFF®
Dermal +
Epidermic Autograft + +
Table 1. Cellular-based tissue-engineered skin products currently in commerce
Engineered epidermal constructs with qualities similar to those of autologous skin have
been used to facilitate repair of split-thickness wounds. Autologous cultured keratinocyte
grafts have been used in humans since the 1980s. As a result there has been extensive experi‐
ence with cultured epidermal grafts for the treatment of burns as well as other acute and
chronic wounds [24]. Although they act as permanent wound coverage, since the host does
not reject them, disadvantages include the two to three week time interval required before
sufficient quantities of keratinocytes are available.
Cultured keratinocyte allografts were developed to overcome the need for biopsy and culti‐
vation to produce autologous grafts and the long lag period between epidermal harvest and
graft production. Cultured epidermal cells from both cadavers and adult donors have been
used for the treatment of burns. Although a previous study showed that allografts made
from neonatal foreskin keratinocytes were more metabolically active than those from cadav‐
er, a recent study has shown that such allografts are immunogenic [16]. As an alternative, a
chemically modified hyaluronic membrane acting as keratinocyte delivery system was de‐
veloped. In this graft cells were delivered to the injury site via a biodegradable scaffold.
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Product Industry Scaffold Type CellSource
Indicated
For Acute
Wounds
Indicated
For Chronic
Wounds
Integra® Integra Lifesciences-USA
Bovine type I
collagen,
chondrotin-6-
sulfate, silicone
Dermal
Xeno - and
synthetic
graft
+ +
Matriderm®
Dr Suvelack Skin &
Healthcare Ag-
Germany
Bovine non-cross-
linked lyofhilized
collagen
+elastinhydrolysate
Dermal Xenograft + +
Unite Biomatrix®
TEVA-
Pharmaceutical
Industries LTD
Equin pericardium
type I collagen
Dermal +
Epidermic Xenograft + +
Matristem™
Wound Care
Matrix
ACELL Inc./Medline Porcine urinarybladder matrix Dermal Xenograft + +
Ez-Derm™ AM Scientific /Brennen Medical
Porcine aldehyde
cross-linked
reconstituted
dermal collagen
Dermal +
Epidermic Xenograft + +
Biodesign®
(Surgisis®) Hernia
Graft
Cook Medical
Porcine small
intestine
submucosa (SIS)
Dermal Xenograft + -
Permacol Covidien
Porcine acellular
diisocyanite cross-
linked dermis
Surgical biological
implant for hernia
& abdominal wall
repair
Xenograft + -
CollaMend
Implant Davol Inc/Bard Porcine Dermis
Surgical biological
implantfor hernia
& abdominal wall
repair
Xenograft + -
XenMatrix
Surgical Graft Davol Inc/Bard Porcine Dermis
Surgical biological
implantfor hernia
& abdominal wall
repair
Xenograft + -
Puracol® Plus
Microscaffold
Collagen(Puracol
Plus Ag)
Dr Suvelack Skin &
Healthcare AG/
Medline
Bovine
Collagen(plus
antimicrobial Ag)
Surgical biological
implantfor hernia
& abdominal wall
repair
Xenograft + -
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Product Industry Scaffold Type CellSource
Indicated
For Acute
Wounds
Indicated
For Chronic
Wounds
Biopad Collagen
Wound Dressing Euroresearch
Equine flexor
tendon Dermal Xenograft + +
OASIS Wound
Matrix
Healthpoint Ltd./
Cook Biotech, Inc
Porcine small
intestine
submucosa (SIS)
Dermal Xenograft + +
Strattice™
Reconstructive
Tissue Matrix
LifeCell Porcine Dermis Dermal Xenograft + +
Endoform™
Dermal Template Mesynthes
Propria submucosa
layers of ovine
forestomach
Dermal Xenograft + -
Veritas Collagen
Matrix
Synovis Orthopedic
and Woundcare Bovine pericardium
Surgical biological
implant for
abdominal wall
repair& breast
reconstruction
Xenograft + -
Primatrix™
Dermal Repair
Scaffold
TEI Biosciences Fetal bovine dermis Dermal Xenograft + -
SurgiMend®/
SurgiMend®Herni
a Repair Matrix
TEI Biosciences Fetal bovine dermis
Surgical biological
implantfor hernia
& abdominal wall
repair
Xenograft + -
Alloderm® KCL/ LifeSciences Human skin tissue Dermal Allograft + -
Hyalomatrix PA® FAB Membrane HYAFF®layered on silicon Dermal
Allo - and
synthetic
graft
+ -
Biobrane® Smith&Nephew
Silicon film, nylon
fabric, porcine
collagen
Dermal +
Epidermic
Xeno - and
synthetic
graft
+ +
Suprathel® Healtcare Polylattic acid Epidermic Xenograft + +
Jaloskin® FAB HYAFF11 Epidermic Xenograft + -
Graftygen
Epidermis® TEVA Mycrolose Epidermic Xenograft + +
Graftygen
Derma® TEVA Collagen (3D) Dermal Allograft + +
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Product Industry Scaffold Type CellSource
Indicated
For Acute
Wounds
Indicated
For Chronic
Wounds
Neoform™ Mentor Human dermis Dermal Allograft + +
Pelnac Standard/
Pelnac Fortified
Gunze Limited,
Medical Material
Center
Silicone/silicone
fortified with
silicone gauze
TRX,Porcine tendon
–derived
atenocollagen
Dermal
Xeno - and
synthetic
graft
+ -
SureDerm
Acellular
Hans Biomed
Corporation
Human acellular
lyofilized dermis Dermal Allograft + +
GraftJacket Wright MedicalTechnology, Inc.
Human acellular
pre-meshed dermis Dermal Allograft + -
Karoderm Karocell TissueEngineering AB
Human acellular
dermis Dermal Allograft + +
AllomaxSurgical
Graft Davol Inc/Bard
Human acellular
dermis
Surgical biological
implant for hernia
& abdominal wall
Allograft + -
Dermamatrix
Acellular Dermis
MusculoskeletalTran
splant Foundation/
Synthes CMF
Human acellular
dermis
Surgical biological
implant for hernia
& abdominal wall
Allograft + -
FlexHD Acellular
Hydrated Dermis
MusculoskeletalTran
splant Foundation/
Ethicon
Human acellular
dermis Dermal Allograft + -
Terudermis Olympus TerumoBiomaterial
Silicone, bovine
lyophilized cross-
linked collagen
sponge made of
heat-denatured
collagen
Dermal
Xeno - and
synthetic
graft
+ -
Table 2. Acellular tissue-engineered skin products in commerce.
Keeping in mind that good skin regeneration requires an appropriate dermal layer, allog‐
rafts (containing dermis) from other sources have been used for many years, although they
provide only temporary coverage due to their tendency to induce acute inflammation. How‐
ever, this skin can be chemically treated to remove the antigenic epidermal cellular elements
and has been used alone or in combination with cultured autologous keratinocytes for clo‐
sure of various chronic wounds and burns. In spite of these modifications, allogeneic grafts,
Skin Grafts58
when compared with autologous grafts, have been shown to promote lower percentages of
re-epithelization and excessive wound contraction [17].
Acellular matrices may be either animal- or human-derived, with all cells removed during
manufacture, or they may be either synthetic or composite, if cells are naturally not present
from the outset. These matrices or tissue scaffolds provide a collagen structure for tissue re‐
modeling, while the removal of viable cells aims to minimize or prevent an inflammatory or
immunogenic response [18]. A matrix may be described as a tissue scaffold in that it pro‐
vides a supporting structure into which cells can migrate. However, it should be noted that
a scaffold does not have to be a matrix (e.g. it does not interact with cells to the same degree
as a matrix). For example, fibronectin may act as a matrix, but it is not necessarily a scaffold;
similarly, polyglactin may act as a scaffold, but it is not a matrix [14].
Given current knowledge, the ideal acellular matrix is one that most closely approximates
the structure and function of the native ECM it is replacing.
An acellular composite skin graft containing bovine collagen and chondroitin-6-sulfate with
an outer silicone covering was developed in the 1980s. After placement on the wound, the
acellular dermal component recruits the host dermal fibroblasts while undergoing simulta‐
neous degradation. About two or three weeks later, the silicone sheet is removed and cov‐
ered with an autograft. This composite graft has been used successfully to treat burns [19].
However, these constructs cannot be used in patients who are allergic to bovine products.
Another type of dermal substitute consists of an inner nylon mesh in which human fibro‐
blasts are embedded, together with an outer silicone layer. After an appropriate time, fibro‐
blasts are laid in the final product by freeze-thawing. Prior to that time, fibroblasts produce
autologous collagen, matrix proteins and cytokines, all of which promote wound healing by
the host. This product has been used successfully as temporary wound coverage after exci‐
sion of burn wounds, until the appearance of the modified product on the market. The new
graft contains a biodegradable polyglactin mesh, in which fibroblasts retain viability, in‐
stead of the nylon mesh. The use of this dermal substitute has had limited success in the
treatment of diabetic foot ulcers, owing largely to its inability to form stable adhesions with
the final epidermal graft [20].
Full-thickness wounds involve the loss of both the epidermal and dermal layers of the skin. To
treat such extensive wounds, a two-layer skin composite was developed consisting of a colla‐
gen sponge containing dermal fibroblasts covered with epidermal cells. A subsequent amend‐
ment  containing  type  I  bovine  collagen  and live  allogeneic  human skin  fibroblasts  and
keratinocytes has been developed. It has been used successfully in surgical wounds and venous
ulcers [21]. In a multicenter trial, this product produced accelerated healing of chronic non-heal‐
ing venous stasis ulcers when compared to standard compressive therapy [22].
Several other composite skin substitutes combining dermal and epidermal elements have
been developed. Composite cultured skin composed of an overlay of stratified neonatal ker‐
atinocytes on fibroblasts embedded in distinct layers of bovine type I collagen is currently
being evaluated in clinical trials for the treatment of burns.
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Currently the acellular matrix products differ mainly in the source of cells and tissue materi‐
als and methods used during manufacture. A variety of animal- and human-derived prod‐
ucts are available (Table 2), as in the reference [14].
Products derived from animal sources (xenografts) are developed by harvesting living tissue
(e.g. dermis, small intestine submucosa, pericardium, etc) from various donor animals (e.g.
porcine, equine or bovine) at different stages of development. The tissue materials are sub‐
sequently processed to remove the cells (decellularization), leaving the collagen matrix.
Products derived from animal sources may either consist of the tissue scaffold only (e.g.
Unite® BioMatrix Collagen Wound Dressing, Synovis) or may be combined with synthetic
materials to create a composite product (e.g. INTEGRA® Bilayer Matrix Wound Dressing,
Integra LifeSciences).
Products derived from human sources, i.e. donated human cadaver skin allografts, undergo
various processes to remove the cells and deactivate or destroy pathogens (e.g. AlloDerm®,
Lifecell; GraftJacket®, Wright Medical).
The mechanisms by which acellular matrices promote wound healing remain to be elucidat‐
ed and there is ample scope for further research. It is known from the literature that chronic
or hard-to-heal wounds are characterized by a disrupted or damaged ECM that cannot sup‐
port wound healing. Treatment strategies that are designed to replace the absent or dysfunc‐
tional ECM may be beneficial [9]. As a result, there is renewed interest in collagen-based
advanced wound care products.
In chronic wounds, there is an excess of MMPs and reduced growth factor activity. Together
these result in the degradation of the ECM. For wound healing to occur the balance between
protease and growth factor activity needs to be adjusted [9]. Research has demonstrated that
topically applied collagen-based products can initiate wound healing by binding to and in‐
activating harmful proteases, while encouraging angiogenesis and formation of granulation
tissue [23].
Current information about the mode of action of acellular matrices is largely based on pre‐
clinical data, mainly from research focusing on a porcine-derived small intestinal submuco‐
sa (SIS) wound matrix. These data show that matrices may:
• Act as a scaffold to support cell ingrowth and granulation tissue formation [24]
• Have receptors that permit fibroblasts to attach to the scaffold [25]
• Stimulate angiogenesis [26]
• Act as a chemoattractant for endothelial cells1 [27]
• Contain/protect growth factors1 [28].
When used as an implant, the acellular matrix appears to be fully incorporated into the
wound. However, when used in a chronic wound, the matrix is eventually displaced and is
not fully incorporated. As such, the role of acellular matrices in chronic wounds is not fully
understood. It has been suggested that they act as a biological cover that modulates the
wound environment to promote normal wound healing.
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In the references [29,30] the Authors suggested the mode of action of collagen-based acellu‐
lar matrix products:
• Chronic wounds contain high levels of MMPs which can:
• Degrade the ECM and growth factors
• Increase inflammatory response
• Reduce cell responsiveness in the wound
• Delay wound healing
• An acellular matrix that closely resembles native ECM may act as a scaffold for:
• MMPs to bind to and break down collagen in the product
• Epithelial cells, fibroblasts and vascular endothelial cells to migrate into and proliferate
• Reduced levels of MMPs to be released back into wound as collagen matrix breaks down,
rebalancing protease and growth factor levels in the wound
• Enhanced wound healing environment, where matrix has been replaced by new collagen
with remodeling of ECM.
Acellular matrices should be considered in wounds that are unresponsive to traditional
wound management modalities or present as a complex surgical wound. Factors to consider
will be dependent on the wound type, underlying etiology, patient suitability and treatment
goal. In a non-healing chronic wound (e.g. diabetic foot ulcer), for example, an acellular ma‐
trix may be selected to replace the damaged ECM, fill the defect and optimize the wound
environment for healing.
In the reference [14] the Authors have proposed an algorithm for application of acellular
matrices in a chronic wound, as reported in Table 3. Previous studies have shown that re‐
duction in the area of the chronic wound during the first four weeks of treatment is a predic‐
tor of complete healing at 12 weeks [31]. If no improvement is seen at this time, there should
be further evaluation of the patient and current treatment strategy.
Our own experience in the treatment of complex leg ulcers is prevalently related to the use
of a dermal matrix that stimulates the production of endogenous collagen, determining the
constitution of a functional dermis (Integra Dermal Regeneration Template). It is a ‘‘semibio‐
logical implant’’ consisting of a two-layered membrane. The thin external pellicle, in sili‐
cone, allows for the immediate closure of the wound, controlling the loss of fluids and
proteins, providing it with mechanical and antibacterial protection [32]. The internal layer
consists of a porous matrix composed of type 1 collagen from bovine tendons and from gly‐
cosaminoglycan (chondroitin-6-sulfate) that produces a histoinductive and histoconductive
action on the mesenchyme, leading to the formation of normal derma. The collagen repre‐
sents only its structural base, whereas the chondroitin (8% of its weight) confers its principal
properties on the matrix. The glycosaminoglycans, such as hyaluronan, dermatan, and kera‐
tan, are important in the constitution of the ECM and in the regulation of the cellular devel‐
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opment and differentiation. They are predominant in the embryonic tissue and accumulate
in fetal wounds, which repair through regeneration without inflammation or scarring in fib‐
rosis [33,34]. The chondroitin, moreover, masks the sites of binding on the collagen, pre-
empting platelet adhesion and the consequent inflammation [35].
Assessment of patient and wound to establish diagnosis and suitability
฀ ฀
Meets criteria (e.g. diabetic, venous, vasculitic,
trauma wound
Does not meet criteria (e.g. severe arterial
disease).
Do not apply matrix
฀
Address intrinsic problems and control
infection ฀
Unable to control infection.
Do not apply matrix
฀
Ensure appropriate wound bed preparation to
maximize healing potential ฀
Wound bed is not viable.
Do not apply matrix
฀
Consider options for treatment
(including acellular/cellular matrix, growth factors, etc)
฀
Wound bed is viable and infection controlled
Apply acellular matrix
Consider adjunctive therapies, for example: NPWT to control exudates, topical antimicrobial to control infection,
compression to control oedema
฀
Review at 7 days
Address any complications, e.g. apply new matrix if product is displaced
Continue to address intrinsic problems and control infection
Change secondary dressing
฀
Continue to observe
฀
Re-epithelization and wound healing
Table 3. Algorithm for application of acellular matrices in a chronic wound [14]
When the Integra is applied to a lesion, the inflammation stops because the matrix not only
seems to be invisible to the platelets and inflammatory leucocytes, but also seems to be rec‐
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ognized as self. One does not find microscopic inflammatory infiltrates or clinical signs of
inflammation. Pain is often absent after the application of Integra, and perilesional erythema
and oedema disappear quickly. The hypotheses that explain the phenomenon can be sum‐
marized as follows. The lack of adhesion of the platelet anticipates the acute inflammation,
and the artificial dermis confines the lesion, eliminating local exposition, desiccation, bio‐
burden, and similar secondary damage. The chondroitin matrix is sufficiently similar to nor‐
mal tissue such that the leukocytes and lymphocytes cross the matrix without recognizing
any abnormality and without thus producing any defensive reaction [36]. In summary,
when the dermal matrix is imposed on a skin lesion, all of the factors that cause damage are
stopped, and from a functional perspective, regeneration is the only available response.
Four distinct phases of regeneration of the dermis were recognized in the period of attach‐
ment of the dermal matrix (imbibition, migration of the fibroblasts, new vascularization, and
maturation with remodeling) without the presence of nerve endings or elastic fibers. The
new collagen is therefore indistinguishable from the normal collagen of the dermis [37].
Compared with the healing obtained with autotransplantation of skin, that achieved using
grafting with Integra are also found to be clinically better and comparable with normal skin [38].
Brought into clinical use in 1981, Integra was first used for the treatment of burns, predomi‐
nantly those that were deep and covering a large area [39-41]. Subsequently, its use was ex‐
tended to reconstructive surgery on strongly retracted scars [42]. It was found to be
particularly useful in covering deep structures such as periosteum and tendons.
Before the application of Integra, the wounds are to be cleaned and disinfected with antibi‐
otic drugs and advanced dressings during periodic close examinations. Once surgery is
planned, the choice of local or epidural anesthesia is based on the number and dimensions
of the ulcers treated. First, surgical debridement of the lesion(s) is performed aiming to re‐
duce the bacterial ratio, level the deep surface of the ulcer, and regulate its edges: we per‐
form surgical cleansing and the preparation of the margins of the ulcers with a hydro-
surgery system. To facilitate and improve modeling and attachment of the dermal matrix, its
margins are modeled with scissors to fit perfectly and fixed to the skin with metal clips or
topical skin adhesive. Petroleum jelly dressing and compressed multilayer bandages are ap‐
plied on the wound. Postoperative treatment consists of antibiotic and analgesic drugs; anal‐
gesic therapy is provided according to the level of patient pain.
The first postoperative medication is administered after 8 days, the metallic clips (if present) are
removed, and the antibiotic therapy suspended. Usually at the first follow-up a notable reduc‐
tion of moisture and surrounding oedema is ascertained. The patients are then treated in the
outpatient clinic with silver dressings every 5 to 7 days, based on the degree of moisture.
After 21 days, the attachment of the artificial dermis is tested. Usually the dermal matrix is
completely integrated with the guest tissue, having formed a new homogeneous and living
derma. The next skin-graft operation is planned and the patient is readmitted for surgery.
The epidermis (0.15–0.25 mm thick) is extracted with dermatome from the front part of the
thigh, treated with mesh graft, and fixed on the lesion with metal clips. The wounds are cov‐
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ered again with petroleum jelly gauze and compressive bandages, and the previous antibiot‐
ic therapy is recommenced. After 8 days, the first follow-up is planned for the removal of
the clips and the first test of the attachment of the graft. This is covered again with silver
medications, and antibiotics are stopped. Further checks are planned weekly until the ulcer
is completely healed. After that, a monthly follow-up is planned.
We performed a prospective observational study from April 2005 to June 2011 enrolling pa‐
tients with leg ulcers that were not healing for at least 1 year. The ulcers were at least 100
cm2 in area (in the case of multiple ulcers of the same limb, the overall surface area was tak‐
en into account) and at least 3 mm deep over at least 50% of the surface area. Patients who
had an obstructive arterial disease were excluded from the study. The dimensions and
depth of the ulcers were measured using the Visitrak digital apparatus (Smith & Nephew
Medical Limited, Hull, UK). For all patients, there was a preliminary culture on the biopsy
of the lesion. All patients' wounds were cleaned and disinfected with antibiotic drugs and
advanced dressings during periodic close examinations at the outpatient clinic of the operat‐
ing Unit.
Once surgery was planned, the patients were informed about the procedure and gave their
written consent. The choice of anaesthetic (local or epidural) was based on the number and
dimensions of the ulcers to be treated. First, surgical debridement of the lesion(s) was per‐
formed aiming to reduce the level of bacteria, level the deep surface of the ulcer, and estab‐
lish the periphery of the dermal matrix to facilitate and improve its modeling and
attachment. The matrix was modeled with scissors to fit perfectly and was applied by fixing
the edges of the matrix to the skin with metal clips or topical skin adhesive (2-octil-cyanoa‐
crylate, Dermabond, Ethicon Inc., Somerville, NJ). The medication was applied with petrole‐
um jelly gauze and compressed multilayer bandage. Postoperative treatment consisted of
antibiotic and analgesic drugs. Analgesic therapy was provided according to the level of
pain that the patient reported. The same nurse evaluated pain using a 10 cm visual analogi‐
cal scale (VAS) from 0 (no pain) to 10 (maximum pain) before the operation and on postop‐
erative day third, eighth, and fifteenth. The first postoperative medication was administered
after 8 days, the metallic clips (if present) were removed and the antibiotic therapy suspend‐
ed. The patients were then treated in the outpatient clinic with silver dressings every 5 to 7
days, based on the degree of the exudates. After 21 days, the attachment of the artificial der‐
mis was tested, and in positive cases, the patient was readmitted for the surgical application
of a "thin" skin graft. The epidermis (0.15-0.25 mm thick) was extracted with dermatome
from the front part of the thigh, treated with mesh graft, and fixed on the lesion with metal
clips. The lesions were covered again with petroleum jelly gauze and compressive bandag‐
es, and the previous antibiotic therapy was recommenced. After 8 days, the first follow-up
was planned for the removal of the clips and the first test of the attachment of the graft. This
was covered again with the silver medication, and antibiotic therapy was stopped. Further
checks were planned weekly until the ulcer was completely healed. After that, a monthly
follow-up was planned. Independent experts photographically documented all of the treat‐
ment phases in all cases.
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Three-hundred eighty-three consecutive patients were admitted to the study: 109 were male
(28.45%) and 274 were female (71.54%). The median age was 64 (range 37–90) years. The ul‐
cers were classified according to their etiology: 135 were lymphovenous (35.24%) (Figures
1-6), 87 venous (22.71%), 69 due to vasculitis (18.01%), 38 cancerous (9.92%), 29 posttraumat‐
ic (7.57%), 18 neuropathic (4.69%) (Figures 7-11), three were due to chemotherapy (0.78%)
one was the consequence of laser therapy (0.26%), and one was the consequence of surgery
(0.26%). In 117 patients (30.05%), the ulcers were located on both legs and were treated con‐
temporaneously with an identical technique, for a total of 646 limbs treated. All of the ulcers
were infected and required targeted antibiotic therapy. The germs identified were Staphylo‐
coccus aureus (50.0%), Pseudomonas aeruginosa (50.0%) Enterobacter cloacae (15.4%), S. ep‐
idermis (15.4%), Proteus mirabilis (7.6%), and Streptococcus Beta-Haemoliticus (7.6%).
Sometimes more than one type of germ was found in the same patient. At the preoperative
evaluation, all of the patients complained of continuous and intense pain, ranging from a
minimum of 6 to a maximum of 10 (average 7.8) on the VAS scale. In 169 patients (44.1%)
who had good cleansing of the ulcer, the Integra was applied using a local anaesthetic, fix‐
ing it to the skin with the Dermabond after debridement of brushing and washing with a
physiological solution. For the other 214 patients (55.8%), 133 (58.8%) of whom had bilateral
lesions and 71 (41.2%) exposed aponeuroses or tendons, the operation was performed using
an epidural anaesthetic. In all of these cases, the surgical cleansing and the preparation of
the margins of the ulcers were performed using a hydro-surgery system, and the Integra
was attached with metal clips.
Figure 1. Lympho-venous ulcer of the right leg lasting for more than 12 months.
At the follow-up on the third day after surgery, all patients reported a substantial reduction
in local pain (median VAS 3.8, range 1–6) which allowed 88 (23.1%) patients to suspend the
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analgesic therapy. At the follow-up on the eighth day, there was a further reduction in the
level of pain (median VAS 2.8, range 1–4). By the third check on the 15th day, the pain re‐
ported had reduced further (median VAS 1.7, range 0–3) and all of the patients were able to
stop the analgesic therapy.
Figure 2. a,b) The same case as figure 1. View after outpatient treatment of the wound and its debridement with Ver‐
sajet hydrosurgery.
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Figure 3. The same case as figure 1. View of the ulcer 1 week after the application of the Integra dermal substitute.
The brightness of the silicone layer is evident.
Figure 4. The same case as figure 1. View of the ulcer 3 weeks after the application of the Integra dermal substitute.
The new dermis is completely reconstructed, and the wound is ready for the epidermis skin graft.
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Figure 5. The same case as figure 1. View of the wound at the end of thin skin graft
Figure 6. The same case as figure 1. View of the wound 2 weeks after thin skin graft, which is completely attached.
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Figure 7. Neuropathic ulcer of the right leg.
Figure 8. The same case as figure 7. Intraoperatory view during wound debridement with Versajet hydrosurgery (ar‐
row).
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Figure 9. The same case as figure 7. View of the ulcer 1 week after the application of the Integra dermal substitute.
Figure 10. The same case as figure 7. View of the ulcer 3 weeks after the application of the Integra dermal substitute.
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Figure 11. The same case as figure 7. View of the wound 2 weeks after thin skin graft..
In all patients, at the first follow-up, a notable reduction in the exudate and the perilesional
oedema was ascertained. After 2 weeks the progressive substitution of granulation tissue
with new yellow or gold derma became evident through the layer of silicone. Only in 50 cas‐
es (7.7%) was it necessary to partially remove the layer of silicone because some areas
showed abundant yellowish exudates under the lamina. The neodermis, remaining thus un‐
covered and without protection, was covered with hydrofibrous and silver dressings, al‐
though that did not prevent, even in these patients, the complete formation of the
neodermis.
At the check on the 21st day, in all cases, the dermal matrix was completely integrated with
the guest tissue, having formed a new homogeneous and living derma, and the next skin-
graft operation was planned.
In 339 patients (88.5%) the attachment of the skin graft was complete, whereas in 44 patients
(11.5%) it was partial but nevertheless larger than 70% of the surface, but, even in these cases,
complete healing of the lesion was achieved within 4 weeks at the most. The definitive result
was therefore the complete healing of all of the lesions. All of the patients were examined in
follow-up visits for a minimum of 3 months; none suffered from an ulcerous recurrence.
According to our experience, in all of the patients suffering from deep and wide leg ulcers,
the use of Integra dermal matrix allowed for the complete refilling of the loss of tissue, with
covering of the uncovered anatomical structures such as tendons and aponeuroses, fast and
occasionally immediate disappearance of pain in almost all cases, and rapid regeneration of
a permanent dermis. The quality, flexibility, and elasticity of the neodermis confirmed the
difference from the scar tissue and its similarity to the normal dermis, resulting in better me‐
chanical resistance of the neodermis and fewer tendencies toward hypertrophy of the scar.
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This therefore allows the application of a thin epidermal skin graft that requires a secure
and faster attachment than a total- or partial-thickness skin graft but also consistent im‐
provement in terms of functional and aesthetic results.
Future directions and research lines in chronic wounds treatment will have to deal with sever‐
al issues. Concerning tissue-engineered products for skin substitution, these have been associ‐
ated with improved survival rate and quality of life in patients with extensive burns [43].
However, despite promising results have been reported in clinical trial with products based
on autologous cultured keratinocytes and fibroblasts [44], actually these can only serve as a
bridge to autografting rather than being suitable for fully replace damaged skin [43,45].
Tissue-engineered tissues cannot replace all skin functions. Protective barrier function is pre‐
served, but touch and temperature sensation, perspiration, thermoregulation, protection from
ultraviolet rays, and synthetic function are not restored [43,45], though several studies have
investigated the possibility of re-establishing other skin functions with the combination of dif‐
ferent cell types [46-48]. Skin-substitute products may be extracted from bone marrow cells
[49], and the addition of skin appendages [50] or signaling molecules regulating cell-cell and
cell-matrix interactions [51] has been studied to further functionalize bioconstructs.
Aesthetic results remain controversial. Issues of cosmesis and quality of life as well as func‐
tionality are nowadays to be considered altogether when dealing with skin-restoration treat‐
ment. Human skin does not regenerate postnatally; postnatal healing consists of repair
rather than regeneration. Skin replacement products obtained from postnatal cellular mate‐
rials are unlikely to obtain a true regeneration, and scarring is almost always the final conse‐
quence of the process [52,53]. As a matter of fact, skin repair results in scars formation.
Uncontrolled scarring may cause possible loss of function where excessive tissue production
and contraction occur, apart of poor aesthetic results. Hence, prevention of scar is a problem
to be addressed after restoration of the damaged skin. Improved understanding of foetal
wound healing has led to therapeutic measures directed at scar-free healing, mainly based
on the principle that scarless healing is facilitated by a decreased inflammatory response
[45,52]. It has been observed that during foetal life growth factors TGF-β1 and TGF-β2 are
low or absent while TGF-β3 is higher; conversely, in adult individuals the latter is insignifi‐
cant and TGF-β1 and –β2 are predominantly expressed during the inflammation phase of
wound healing [54]. A complex interplay of these isoforms is crucial for optimal healing re‐
sults, as studies on pig and human succeeded in reducing scarring by selectively increasing
TGF-β3 and inhibiting TGF-β1 and -β2 levels, whilst neutralization of all three isoforms did
not result in reduced scarring [54,55].
The role of stem cells has also been investigated. Both embryonic and adult stem cells have
been used in several trials, but research on the former still is delayed by ethical debate.
Adult stem cells are being used widely in different research fields. However, results are not
as brilliant as expected, due to the impossibility of identifying a stem cell within human skin
tissue without ambiguity [50,56,57] and also to unsuitable biochemical and mechanical con‐
ditions in a wound which may limit plasticity and proliferative activity of implanted stem
cells [57]. Nevertheless, experimental studies conducted on murine models [50,58,59] sug‐
gest that research on stem cells should be encouraged as it may achieve production of fully
functional true skin equivalents should pattern of cell differentiation be identified in human.
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